Download PDF
Semin Liver Dis 2015; 35(04): 421-431
DOI: 10.1055/s-0035-1567829
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis

Guruprasad P. Aithal
1   National Institute for Health Research (NIHR), Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, United Kingdom
,
Jane I. Grove
1   National Institute for Health Research (NIHR), Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
16 December 2015 (online)

    Permissions and Reprints

Abstract

Hepatotoxicity constrains drug development and accounts for a substantial burden on health services. Genome-wide association studies (GWASs) have investigated potential genetic factors that explain interindividual variations in response to medications leading to drug-induced liver injury (DILI). Although the proportion of GWASs investigating DILI is very small, those that have focused on this area have identified risk alleles with substantially higher risk ratios for susceptibility to DILI when compared with GWASs involving the majority of other complex diseases. Moreover, a relatively small number of human leukocyte antigen alleles are associated with DILI secondary to a range of medications. Because the encoded major histocompatibility complex proteins mediate antigen presentation to T cells, this provides evidence for a crucial central role for the adaptive immune system in DILI. Findings of GWASs should be considered during preclinical development of certain drugs. Genotyping may also have clinical applications, although it is currently limited to particular scenarios in relation to specific drugs.

Keywords

genome-wide association studies - drug-induced liver injury - hepatotoxicity - human leukocyte antigen - pharmacogenetics
 

  • References

  • 1 Aithal GP, Watkins PB, Andrade RJ , et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89 (6) 806-815
    CrossrefPubMedGoogle Scholar
  • 2 Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 2009; 14 (3–4) 162-167
    CrossrefPubMedGoogle Scholar
  • 3 Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144 (7) 1419-1425 , 1425.e1–1425.e3, quiz e19–e20
    CrossrefPubMedGoogle Scholar
  • 4 Donaghy L, Barry FJ, Hunter JG , et al. Clinical and laboratory features and natural history of seronegative hepatitis in a nontransplant centre. Eur J Gastroenterol Hepatol 2013; 25 (10) 1159-1164
    PubMedGoogle Scholar
  • 5 Reuben A, Koch DG, Lee WM ; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52 (6) 2065-2076
    CrossrefPubMedGoogle Scholar
  • 6 Ulrich RG. Idiosyncratic toxicity: a convergence of risk factors. Annu Rev Med 2007; 58: 17-34
    CrossrefPubMedGoogle Scholar
  • 7 Björnsson E, Aithal G. Immune-mediated drug-induced liver injury. In: Gershwin ME, Vierling JM, Manns MP, eds. Liver Immunology. Heidelberg, Germany: Springer International Publishing; 2014: 401-412
    CrossrefGoogle Scholar
  • 8 Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132 (1) 272-281
    CrossrefPubMedGoogle Scholar
  • 9 Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol 2011; 7 (3) 139-150
    CrossrefPubMedGoogle Scholar
  • 10 Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 2007; 11 (3) 563-575 , vi–vii vi–vii
    CrossrefPubMedGoogle Scholar
  • 11 Hautekeete ML, Horsmans Y, Van Waeyenberge C , et al. HLA association of amoxicillin-clavulanate—induced hepatitis. Gastroenterology 1999; 117 (5) 1181-1186
    CrossrefPubMedGoogle Scholar
  • 12 O'Donohue J, Oien KA, Donaldson P , et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47 (5) 717-720
    CrossrefPubMedGoogle Scholar
  • 13 Donaldson PT, Daly AK, Henderson J , et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010; 53 (6) 1049-1053
    CrossrefPubMedGoogle Scholar
  • 14 Cai Y, Yi J, Zhou C, Shen X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS ONE 2012; 7 (10) e47769
    CrossrefPubMedGoogle Scholar
  • 15 Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis 2014; 34 (2) 123-133
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Holmes MV, Casas JP, Hingorani AD. Putting genomics into practice. BMJ 2011; 343: d4953
    CrossrefPubMedGoogle Scholar
  • 17 Hindorff LAMJ, Morales J, Junkins HA, Hall PN, Klemm AK, Manolio TA. A catalog of published genome-wide association studies. Available at: www.genome.gov/gwastudies . Accessed January 22, 2015
    PubMedGoogle Scholar
  • 18 Kindmark A, Jawaid A, Harbron CG , et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8 (3) 186-195
    CrossrefPubMedGoogle Scholar
  • 19 Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997; 41 (4) 534-540
    CrossrefPubMedGoogle Scholar
  • 20 Daly AK, Donaldson PT, Bhatnagar P , et al; DILIGEN Study; International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41 (7) 816-819
    CrossrefPubMedGoogle Scholar
  • 21 Baldo BA, Pham NH, Weiner J. Detection and side-chain specificity of IgE antibodies to flucloxacillin in allergic subjects. J Molecul Recogn 1995; 8: 171-177
    PubMedGoogle Scholar
  • 22 Monshi MM, Faulkner L, Gibson A , et al. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013; 57 (2) 727-739
    CrossrefPubMedGoogle Scholar
  • 23 Wuillemin N, Terracciano L, Beltraminelli H , et al. T cells infiltrate the liver and kill hepatocytes in HLA-B(*)57:01-associated floxacillin-induced liver injury. Am J Pathol 2014; 184 (6) 1677-1682
    CrossrefPubMedGoogle Scholar
  • 24 Andrews E, Armstrong M, Tugwood J , et al. A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 2010; 51 (5) 1656-1664
    CrossrefPubMedGoogle Scholar
  • 25 Singer JB, Lewitzky S, Leroy E , et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010; 42 (8) 711-714
    CrossrefPubMedGoogle Scholar
  • 26 Spraggs CF, Budde LR, Briley LP , et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011; 29 (6) 667-673
    CrossrefPubMedGoogle Scholar
  • 27 Schaid DJ, Spraggs CF, McDonnell SK , et al. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Oncol 2014; 32 (22) 2296-2303
    CrossrefPubMedGoogle Scholar
  • 28 Lucena MI, Molokhia M, Shen Y , et al; Spanish DILI Registry; EUDRAGENE; DILIN; DILIGEN; International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141 (1) 338-347
    CrossrefPubMedGoogle Scholar
  • 29 Stephens C, López-Nevot MA, Ruiz-Cabello F , et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS ONE 2013; 8 (7) e68111
    CrossrefPubMedGoogle Scholar
  • 30 Saide K, Kim S, Yuan Y , et al. Identification of susceptible HLA class II co-amoxiclav genotypes based on the analysis of drug-specific T-cells from patients with liver injury. Clin Translation Allerg 2014; 4 (Suppl. 03) O3
    PubMedGoogle Scholar
  • 31 Urban TJ, Shen Y, Stolz A , et al; Drug-Induced Liver Injury Network; DILIGEN; EUDRAGENE; Spanish DILI Registry; International Serious Adverse Events Consortium. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012; 22 (11) 784-795
    CrossrefPubMedGoogle Scholar
  • 32 Ahmadi KR, Weale ME, Xue ZY , et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 2005; 37 (1) 84-89
    PubMedGoogle Scholar
  • 33 Hindorff LA, Sethupathy P, Junkins HA , et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 2009; 106 (23) 9362-9367
    CrossrefPubMedGoogle Scholar
  • 34 Tokunaga K. Lessons from genome-wide search for disease-related genes with special reference to HLA-disease associations. Genes (Basel) 2014; 5 (1) 84-96
    CrossrefPubMedGoogle Scholar
  • 35 Daly AK. Pharmacogenomics of adverse drug reactions. Genome Med 2013; 5 (1) 5
    CrossrefPubMedGoogle Scholar
  • 36 Kaniwa N, Saito Y. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. J Hum Genet 2013; 58 (6) 317-326
    CrossrefPubMedGoogle Scholar
  • 37 Yip VLM, Alfirevic A, Pirmohamed M. Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol 2015; 48 (2–3) 165-175
    CrossrefPubMedGoogle Scholar
  • 38 Donaldson P. Immunogenetics of autoimmune liver disease. In: Gershwin ME, Vierling J, Manns M, eds. Liver Immunology. New York, NY: Humana Press; 2007: 221-233
    CrossrefGoogle Scholar
  • 39 Hirata K, Takagi H, Yamamoto M , et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2008; 8 (1) 29-33
    CrossrefPubMedGoogle Scholar
  • 40 Kurosaki M, Takagi H, Mori M. HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin. Dig Dis Sci 2000; 45 (6) 1103-1108
    CrossrefPubMedGoogle Scholar
  • 41 Pariente EA, Hamoud A, Goldfain D , et al. [Hepatitis caused by clometacin (Dupéran). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis?]. Gastroenterol Clin Biol 1989; 13 (10) 769-774
    PubMedGoogle Scholar
  • 42 Phillips E, Bartlett JA, Sanne I , et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr 2013; 62 (2) e55-e57
    CrossrefPubMedGoogle Scholar
  • 43 Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166 (7) 916-919
    CrossrefPubMedGoogle Scholar
  • 44 Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis 2009; 29 (4) 383-392
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Aithal GP, Ramsay L, Daly AK , et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39 (5) 1430-1440
    CrossrefPubMedGoogle Scholar
  • 46 Jenkins RE, Meng X, Elliott VL, Kitteringham NR, Pirmohamed M, Park BK. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin Appl 2009; 3 (6) 720-729
    CrossrefPubMedGoogle Scholar
  • 47 Ostrov DA, Grant BJ, Pompeu YA , et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 2012; 109 (25) 9959-9964
    CrossrefPubMedGoogle Scholar
  • 48 Norcross MA, Luo S, Lu L , et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012; 26 (11) F21-F29
    CrossrefPubMedGoogle Scholar
  • 49 Illing PT, Vivian JP, Dudek NL , et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012; 486 (7404) 554-558
    PubMedGoogle Scholar
  • 50 Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2012; 13 (11) 1285-1306
    CrossrefPubMedGoogle Scholar
  • 51 Bharadwaj M, Illing P, Theodossis A, Purcell AW, Rossjohn J, McCluskey J. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol 2012; 52: 401-431
    CrossrefPubMedGoogle Scholar
  • 52 Wuillemin N, Adam J, Fontana S, Krähenbühl S, Pichler WJ, Yerly D. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. J Immunol 2013; 190 (10) 4956-4964
    CrossrefPubMedGoogle Scholar
  • 53 Pichler WJ. Consequences of drug binding to immune receptors: Immune stimulation following pharmacological interaction with immune receptors (T-cell receptor for antigen or human leukocyte antigen) with altered peptide-human leukocyte antigen or peptide. Dermatol Sin 2013; 31: 181-190
    CrossrefPubMedGoogle Scholar
  • 54 Adam J, Pichler WJ, Yerly D. Delayed drug hypersensitivity: models of T-cell stimulation. Br J Clin Pharmacol 2011; 71 (5) 701-707
    CrossrefPubMedGoogle Scholar
  • 55 Zanni MP, von Greyerz S, Schnyder B , et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998; 102 (8) 1591-1598
    CrossrefPubMedGoogle Scholar
  • 56 Bast BJ, Zhou LJ, Freeman GJ , et al. The HB-6, CDw75, and CD76 differentiation antigens are unique cell-surface carbohydrate determinants generated by the beta-galactoside alpha 2,6-sialyltransferase. J Cell Biol 1992; 116 (2) 423-435
    CrossrefPubMedGoogle Scholar
  • 57 Hennet T, Chui D, Paulson JC, Marth JD. Immune regulation by the ST6Gal sialyltransferase. Proc Natl Acad Sci U S A 1998; 95 (8) 4504-4509
    CrossrefPubMedGoogle Scholar
  • 58 Dalziel M, Lemaire S, Ewing J, Kobayashi L, Lau JT. Hepatic acute phase induction of murine beta-galactoside alpha 2,6 sialyltransferase (ST6Gal I) is IL-6 dependent and mediated by elevation of exon H-containing class of transcripts. Glycobiology 1999; 9 (10) 1003-1008
    CrossrefPubMedGoogle Scholar
  • 59 Djurovic S, Le Hellard S, Kähler AK , et al. Association of MCTP2 gene variants with schizophrenia in three independent samples of Scandinavian origin (SCOPE). Psychiatry Res 2009; 168 (3) 256-258
    CrossrefPubMedGoogle Scholar
  • 60 Mell B, Abdul-Majeed S, Kumarasamy S , et al. Multiple blood pressure loci with opposing blood pressure effects on rat chromosome 1 in a homologous region linked to hypertension on human chromosome 15. Hypertens Res 2015; 38 (1) 61-67
    CrossrefPubMedGoogle Scholar
  • 61 Zhang Y, Johansson E, Miller ML , et al. Identification of a conserved anti-apoptotic protein that modulates the mitochondrial apoptosis pathway. PLoS ONE 2011; 6 (9) e25284
    CrossrefPubMedGoogle Scholar
  • 62 Kaur J, Sanyal SN. Modulation of inflammatory changes in early stages of colon cancer through activation of PPARgamma by diclofenac. Eur J Cancer Prev 2010; 19 (5) 319-327
    CrossrefPubMedGoogle Scholar
  • 63 Korman BD, Kastner DL, Gregersen PK, Remmers EF. STAT4: genetics, mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep 2008; 8 (5) 398-403
    CrossrefPubMedGoogle Scholar
  • 64 Urban TJ, Goldstein DB, Watkins PB. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?. Pharmacogenomics 2012; 13 (7) 735-738
    CrossrefPubMedGoogle Scholar
  • 65 Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 2009; 10 (9) 1467-1487
    CrossrefPubMedGoogle Scholar
  • 66 Maher B. Personal genomes: The case of the missing heritability. Nature 2008; 456 (7218) 18-21
    PubMedGoogle Scholar
  • 67 Musani SK, Shriner D, Liu N , et al. Detection of gene x gene interactions in genome-wide association studies of human population data. Hum Hered 2007; 63 (2) 67-84
    CrossrefPubMedGoogle Scholar
  • 68 Patel SJ, Milwid JM, King KR , et al. Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol 2012; 30 (2) 179-183
    CrossrefPubMedGoogle Scholar
  • 69 Berry C. Hazardous products: Cut animal wastage in toxicology testing. Nature 2015; 523 (7561) 410
    PubMedGoogle Scholar
  • 70 Food and Drug Administration. Guidance for industry clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling. Silver Spring, MD: Food and Drug Administration, Office of Communications; 2013
    Google Scholar
  • 71 Alfirevic A, Pirmohamed M. Predictive genetic testing for drug-induced liver injury: considerations of clinical utility. Clin Pharmacol Ther 2012; 92 (3) 376-380
    CrossrefPubMedGoogle Scholar
  • 72 Guo Y, Shi L, Hong H, Su Z, Fuscoe J, Ning B. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci 2013; 56 (2) 119-124
    CrossrefPubMedGoogle Scholar
  • 73 El Sherrif Y, Potts JR, Howard MR , et al. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations?. Liver Int 2013; 33 (8) 1266-1270
    CrossrefPubMedGoogle Scholar
  • 74 Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int 2015; 35 (7) 1801-1808
    CrossrefPubMedGoogle Scholar
  • 75 Daly AK. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu Rev Pharmacol Toxicol 2012; 52: 21-35
    CrossrefPubMedGoogle Scholar
  • 76 Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 2014; 146 (4) 914-928
    CrossrefPubMedGoogle Scholar
  • 77 Heap GA, Weedon MN, Bewshea CM , et al; International Serious Adverse Events Consortium; IBD Pharmacogenetics Study Group. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 2014; 46 (10) 1131-1134
    CrossrefPubMedGoogle Scholar